Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-03-03

AUTHORS

Caroline Rousseau, Ludovic Ferrer, Stéphane Supiot, Manuel Bardiès, François Davodeau, Alain Faivre-Chauvet, Pierre Baumgartner, John Wijdenes, Marie Lacombe, Jacques Barbet, Thierry Guillaume, Philippe Moreau, Jean Luc Harousseau, Françoise Kraeber-Bodéré, Michel Cherel

ABSTRACT

Syndecan-1 (CD138), a heparan sulfate proteoglycan, is constantly expressed on tumor cells in multiple myeloma (MM). This surface antigen is an attractive candidate for targeted therapy, especially radioimmunotherapy (RAIT). We report preliminary biodistribution and dosimetry results obtained in refractory MM patients in a phase I/II RAIT study using iodine-131-labeled anti-CD138 (B-B4) monoclonal antibody (mAb). Four patients with progressive disease were enrolled after three lines of therapy. They received 370 MBq (20 mg/m2) of 131I-B-B4 for the dosimetry study. Each patient underwent a whole body (WB) CT and four WB emission scans at days D0, D1, and D3–4. Images were corrected for attenuation and scatter to assess doses absorbed by organs and bone marrow (BM). Blood and urine samples were additionally collected. Dosimetry was conducted using the MIRD method. Images obtained 1 h after 131I-B-B4 injection showed high BM and liver uptake without kidney uptake. The BM uptake confirmed BM involvement as detected by pre-inclusion FDG PET/CT. Absorbed doses were calculated at 2.03 ± 0.3 mGy/MBq for the liver, 1.10 ± 0.9 mGy/MBq for the kidneys, and 0.52 ± 0.20 mGy/MBq for the BM. Grade III thrombocytopenia was documented in two cases (highest BM-absorbed doses), and no grade IV hematological toxicity was observed. Therefore, autologous stem cells were not infused. One patient out of four experienced partial response, with 60% reduction of M-spike on serum electrophoresis, and total relief of pain, lasting for 1 year. This patient was able to go back to work. In this proof of concept study based on dosimetry, we show that MM RAIT is feasible using the anti-CD138 antibody. It would be of great interest to perform a RAIT phase I/II trial with a humanized anti-CD138 mAb with increased doses and systematic autologous stem cell infusions to overcome hematological toxicity and achieve efficacy. More... »

PAGES

679-688

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13277-012-0362-y

DOI

http://dx.doi.org/10.1007/s13277-012-0362-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1003557788

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22389160


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoconjugates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iodine Radioisotopes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multimodal Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron-Emission Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radioimmunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiometry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Syndecan-1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tomography, X-Ray Computed", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Nuclear Medicine Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France", 
            "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rousseau", 
        "givenName": "Caroline", 
        "id": "sg:person.01240530667.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Physics Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France", 
            "Medical Physics Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferrer", 
        "givenName": "Ludovic", 
        "id": "sg:person.01112242163.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112242163.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radiotherapy Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France", 
            "Radiotherapy Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Supiot", 
        "givenName": "St\u00e9phane", 
        "id": "sg:person.01137036366.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137036366.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bardi\u00e8s", 
        "givenName": "Manuel", 
        "id": "sg:person.01001125170.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001125170.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davodeau", 
        "givenName": "Fran\u00e7ois", 
        "id": "sg:person.01105624024.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105624024.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine Department, University Hospital, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France", 
            "Nuclear Medicine Department, University Hospital, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Faivre-Chauvet", 
        "givenName": "Alain", 
        "id": "sg:person.01334456404.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334456404.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Nuclear Medicine Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baumgartner", 
        "givenName": "Pierre", 
        "id": "sg:person.016576267377.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016576267377.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diaclone, Besancon, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Diaclone, Besancon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wijdenes", 
        "givenName": "John", 
        "id": "sg:person.01157114464.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157114464.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Nuclear Medicine Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lacombe", 
        "givenName": "Marie", 
        "id": "sg:person.01145011737.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145011737.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barbet", 
        "givenName": "Jacques", 
        "id": "sg:person.01001654663.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001654663.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hematology Department, University Hospital, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "Hematology Department, University Hospital, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guillaume", 
        "givenName": "Thierry", 
        "id": "sg:person.01151435377.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151435377.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hematology Department, University Hospital, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "Hematology Department, University Hospital, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moreau", 
        "givenName": "Philippe", 
        "id": "sg:person.0732370777.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732370777.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France", 
          "id": "http://www.grid.ac/institutes/grid.418189.d", 
          "name": [
            "Hematology Department, University Hospital, Nantes, France", 
            "Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harousseau", 
        "givenName": "Jean Luc", 
        "id": "sg:person.0774254522.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774254522.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine Department, University Hospital, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "Nuclear Medicine Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France", 
            "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France", 
            "Nuclear Medicine Department, University Hospital, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kraeber-Bod\u00e9r\u00e9", 
        "givenName": "Fran\u00e7oise", 
        "id": "sg:person.0653324404.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Nuclear Medicine Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France", 
            "Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cherel", 
        "givenName": "Michel", 
        "id": "sg:person.01224071104.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224071104.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s002590050306", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015921857", 
          "https://doi.org/10.1007/s002590050306"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-005-1803-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025046486", 
          "https://doi.org/10.1007/s00259-005-1803-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2008.291", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002132702", 
          "https://doi.org/10.1038/leu.2008.291"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1997.409", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019429566", 
          "https://doi.org/10.1038/bjc.1997.409"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002620050289", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039961050", 
          "https://doi.org/10.1007/s002620050289"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10585-007-9125-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029972570", 
          "https://doi.org/10.1007/s10585-007-9125-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-03-03", 
    "datePublishedReg": "2012-03-03", 
    "description": "Syndecan-1 (CD138), a heparan sulfate proteoglycan, is constantly expressed on tumor cells in multiple myeloma (MM). This surface antigen is an attractive candidate for targeted therapy, especially radioimmunotherapy (RAIT). We report preliminary biodistribution and dosimetry results obtained in refractory MM patients in a phase I/II RAIT study using iodine-131-labeled anti-CD138 (B-B4) monoclonal antibody (mAb). Four patients with progressive disease were enrolled after three lines of therapy. They received 370\u00a0MBq (20\u00a0mg/m2) of 131I-B-B4 for the dosimetry study. Each patient underwent a whole body (WB) CT and four WB emission scans at days D0, D1, and D3\u20134. Images were corrected for attenuation and scatter to assess doses absorbed by organs and bone marrow (BM). Blood and urine samples were additionally collected. Dosimetry was conducted using the MIRD method. Images obtained 1\u00a0h after 131I-B-B4 injection showed high BM and liver uptake without kidney uptake. The BM uptake confirmed BM involvement as detected by pre-inclusion FDG PET/CT. Absorbed doses were calculated at 2.03\u2009\u00b1\u20090.3\u00a0mGy/MBq for the liver, 1.10\u2009\u00b1\u20090.9\u00a0mGy/MBq for the kidneys, and 0.52\u2009\u00b1\u20090.20\u00a0mGy/MBq for the BM. Grade III thrombocytopenia was documented in two cases (highest BM-absorbed doses), and no grade IV hematological toxicity was observed. Therefore, autologous stem cells were not infused. One patient out of four experienced partial response, with 60% reduction of M-spike on serum electrophoresis, and total relief of pain, lasting for 1\u00a0year. This patient was able to go back to work. In this proof of concept study based on dosimetry, we show that MM RAIT is feasible using the anti-CD138 antibody. It would be of great interest to perform a RAIT phase I/II trial with a humanized anti-CD138 mAb with increased doses and systematic autologous stem cell infusions to overcome hematological toxicity and achieve efficacy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13277-012-0362-y", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1091981", 
        "issn": [
          "1010-4283", 
          "1423-0380"
        ], 
        "name": "Tumor Biology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "33"
      }
    ], 
    "keywords": [
      "bone marrow", 
      "hematological toxicity", 
      "multiple myeloma", 
      "phase I/II trial", 
      "grade IV hematological toxicity", 
      "autologous stem cell infusion", 
      "FDG PET/CT", 
      "refractory MM patients", 
      "high bone marrow", 
      "grade III thrombocytopenia", 
      "experienced partial response", 
      "feasibility of radioimmunotherapy", 
      "anti-CD138 antibodies", 
      "lines of therapy", 
      "stem cell infusion", 
      "multiple myeloma patients", 
      "whole-body CT", 
      "PET/CT", 
      "autologous stem cells", 
      "BM uptake", 
      "II trial", 
      "progressive disease", 
      "BM involvement", 
      "partial response", 
      "MM patients", 
      "cell infusion", 
      "myeloma patients", 
      "CD138 antibody", 
      "body CT", 
      "kidney uptake", 
      "serum electrophoresis", 
      "liver uptake", 
      "patients", 
      "total relief", 
      "surface antigen", 
      "M-spike", 
      "MIRD method", 
      "day D0", 
      "dosimetry results", 
      "syndecan-1", 
      "tumor cells", 
      "radioimmunotherapy", 
      "monoclonal antibodies", 
      "urine samples", 
      "heparan sulfate proteoglycan", 
      "MBq", 
      "doses", 
      "antibodies", 
      "preliminary biodistribution", 
      "therapy", 
      "sulfate proteoglycan", 
      "stem cells", 
      "dosimetry studies", 
      "CT", 
      "concept study", 
      "emission scans", 
      "toxicity", 
      "D3-4", 
      "uptake", 
      "thrombocytopenia", 
      "cells", 
      "pain", 
      "myeloma", 
      "infusion", 
      "kidney", 
      "marrow", 
      "antigen", 
      "disease", 
      "liver", 
      "blood", 
      "trials", 
      "study", 
      "efficacy", 
      "scans", 
      "biodistribution", 
      "injection", 
      "organs", 
      "relief", 
      "D1", 
      "involvement", 
      "dosimetry", 
      "proteoglycans", 
      "attractive candidate", 
      "years", 
      "response", 
      "cases", 
      "reduction", 
      "results", 
      "attenuation", 
      "candidates", 
      "samples", 
      "electrophoresis", 
      "lines", 
      "feasibility", 
      "great interest", 
      "D0", 
      "images", 
      "method", 
      "interest", 
      "proof", 
      "work", 
      "scatter"
    ], 
    "name": "Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients", 
    "pagination": "679-688", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1003557788"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13277-012-0362-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22389160"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13277-012-0362-y", 
      "https://app.dimensions.ai/details/publication/pub.1003557788"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_555.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13277-012-0362-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13277-012-0362-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13277-012-0362-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13277-012-0362-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13277-012-0362-y'


 

This table displays all metadata directly associated to this object as RDF triples.

367 TRIPLES      21 PREDICATES      148 URIs      134 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13277-012-0362-y schema:about N053cb9932abe49a4a811e002ac8602de
2 N0e0c29e53cba4e269da1432a9101ed03
3 N289e27e110a949e2a17ac7ff3470bbcd
4 N4986c293075144f1a9dfac7ae8718e86
5 N51130c74c4b94a048077607f3ebd858a
6 N5748f7a8ef1147f794eb05c5c2c286b5
7 N7c64c6c6052848a888cf75f490ff798c
8 N819f6b74694f41a1b251e238d22b431b
9 N9918f29ce04a4d1c9cb9832ae7ebd7fe
10 Na008c97f5b704285a85cadf85defcd80
11 Na1831bb965774a63a5dcdbcb665fda19
12 Nb8e7d816f2c3439caf9d31c9fc0a5159
13 Nbba8fa72b15c425a8a0c1ff73105e5f4
14 Neb5505af45ba4573b1af397376855d72
15 Nf89f3c6c970e48e1bfb769cc6a1f2f86
16 anzsrc-for:11
17 anzsrc-for:1115
18 schema:author Necd1775eca2146118a45055f1f2e04fe
19 schema:citation sg:pub.10.1007/s00259-005-1803-2
20 sg:pub.10.1007/s002590050306
21 sg:pub.10.1007/s002620050289
22 sg:pub.10.1007/s10585-007-9125-3
23 sg:pub.10.1038/bjc.1997.409
24 sg:pub.10.1038/leu.2008.291
25 schema:datePublished 2012-03-03
26 schema:datePublishedReg 2012-03-03
27 schema:description Syndecan-1 (CD138), a heparan sulfate proteoglycan, is constantly expressed on tumor cells in multiple myeloma (MM). This surface antigen is an attractive candidate for targeted therapy, especially radioimmunotherapy (RAIT). We report preliminary biodistribution and dosimetry results obtained in refractory MM patients in a phase I/II RAIT study using iodine-131-labeled anti-CD138 (B-B4) monoclonal antibody (mAb). Four patients with progressive disease were enrolled after three lines of therapy. They received 370 MBq (20 mg/m2) of 131I-B-B4 for the dosimetry study. Each patient underwent a whole body (WB) CT and four WB emission scans at days D0, D1, and D3–4. Images were corrected for attenuation and scatter to assess doses absorbed by organs and bone marrow (BM). Blood and urine samples were additionally collected. Dosimetry was conducted using the MIRD method. Images obtained 1 h after 131I-B-B4 injection showed high BM and liver uptake without kidney uptake. The BM uptake confirmed BM involvement as detected by pre-inclusion FDG PET/CT. Absorbed doses were calculated at 2.03 ± 0.3 mGy/MBq for the liver, 1.10 ± 0.9 mGy/MBq for the kidneys, and 0.52 ± 0.20 mGy/MBq for the BM. Grade III thrombocytopenia was documented in two cases (highest BM-absorbed doses), and no grade IV hematological toxicity was observed. Therefore, autologous stem cells were not infused. One patient out of four experienced partial response, with 60% reduction of M-spike on serum electrophoresis, and total relief of pain, lasting for 1 year. This patient was able to go back to work. In this proof of concept study based on dosimetry, we show that MM RAIT is feasible using the anti-CD138 antibody. It would be of great interest to perform a RAIT phase I/II trial with a humanized anti-CD138 mAb with increased doses and systematic autologous stem cell infusions to overcome hematological toxicity and achieve efficacy.
28 schema:genre article
29 schema:isAccessibleForFree false
30 schema:isPartOf N2bb3be25ed8e41f3aa323a80dbab9109
31 Ncab0369f688a4c729dd0e71b57980dd1
32 sg:journal.1091981
33 schema:keywords BM involvement
34 BM uptake
35 CD138 antibody
36 CT
37 D0
38 D1
39 D3-4
40 FDG PET/CT
41 II trial
42 M-spike
43 MBq
44 MIRD method
45 MM patients
46 PET/CT
47 anti-CD138 antibodies
48 antibodies
49 antigen
50 attenuation
51 attractive candidate
52 autologous stem cell infusion
53 autologous stem cells
54 biodistribution
55 blood
56 body CT
57 bone marrow
58 candidates
59 cases
60 cell infusion
61 cells
62 concept study
63 day D0
64 disease
65 doses
66 dosimetry
67 dosimetry results
68 dosimetry studies
69 efficacy
70 electrophoresis
71 emission scans
72 experienced partial response
73 feasibility
74 feasibility of radioimmunotherapy
75 grade III thrombocytopenia
76 grade IV hematological toxicity
77 great interest
78 hematological toxicity
79 heparan sulfate proteoglycan
80 high bone marrow
81 images
82 infusion
83 injection
84 interest
85 involvement
86 kidney
87 kidney uptake
88 lines
89 lines of therapy
90 liver
91 liver uptake
92 marrow
93 method
94 monoclonal antibodies
95 multiple myeloma
96 multiple myeloma patients
97 myeloma
98 myeloma patients
99 organs
100 pain
101 partial response
102 patients
103 phase I/II trial
104 preliminary biodistribution
105 progressive disease
106 proof
107 proteoglycans
108 radioimmunotherapy
109 reduction
110 refractory MM patients
111 relief
112 response
113 results
114 samples
115 scans
116 scatter
117 serum electrophoresis
118 stem cell infusion
119 stem cells
120 study
121 sulfate proteoglycan
122 surface antigen
123 syndecan-1
124 therapy
125 thrombocytopenia
126 total relief
127 toxicity
128 trials
129 tumor cells
130 uptake
131 urine samples
132 whole-body CT
133 work
134 years
135 schema:name Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients
136 schema:pagination 679-688
137 schema:productId N3d4159c709c44734a7807d10031619af
138 Nb631c3aee99e4ce5b132d9317e8728b6
139 Ne67b5d8fbb8643c4b18991871a9988c4
140 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003557788
141 https://doi.org/10.1007/s13277-012-0362-y
142 schema:sdDatePublished 2022-12-01T06:29
143 schema:sdLicense https://scigraph.springernature.com/explorer/license/
144 schema:sdPublisher Nb751b69ab02741e49943fb97d16ca5f6
145 schema:url https://doi.org/10.1007/s13277-012-0362-y
146 sgo:license sg:explorer/license/
147 sgo:sdDataset articles
148 rdf:type schema:ScholarlyArticle
149 N0398ba0dca5d4968b0034c3a08ff0987 rdf:first sg:person.01334456404.06
150 rdf:rest N441bc469b4ee4348948eb99567d985ef
151 N053cb9932abe49a4a811e002ac8602de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Female
153 rdf:type schema:DefinedTerm
154 N0d54fbbc54ed4169816511fbe25317ed rdf:first sg:person.01145011737.42
155 rdf:rest N90345f1acc9e4f5bb6079aa368ecd48a
156 N0e0c29e53cba4e269da1432a9101ed03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Radioimmunotherapy
158 rdf:type schema:DefinedTerm
159 N27698898e3dd4300932dfa38f9de1e84 rdf:first sg:person.01137036366.77
160 rdf:rest N53ff2f0a71c24289b44d6fee9ef79e10
161 N289e27e110a949e2a17ac7ff3470bbcd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Positron-Emission Tomography
163 rdf:type schema:DefinedTerm
164 N2bb3be25ed8e41f3aa323a80dbab9109 schema:volumeNumber 33
165 rdf:type schema:PublicationVolume
166 N3d4159c709c44734a7807d10031619af schema:name pubmed_id
167 schema:value 22389160
168 rdf:type schema:PropertyValue
169 N42599233534c47e2a2d78bf26fc43fa1 rdf:first sg:person.0732370777.35
170 rdf:rest Nfb5557a1833341a4852e94da2a19a52b
171 N441bc469b4ee4348948eb99567d985ef rdf:first sg:person.016576267377.88
172 rdf:rest Nd22a09e179144cfeb5d0bc533f826a26
173 N4986c293075144f1a9dfac7ae8718e86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Tomography, X-Ray Computed
175 rdf:type schema:DefinedTerm
176 N51130c74c4b94a048077607f3ebd858a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Multiple Myeloma
178 rdf:type schema:DefinedTerm
179 N53ff2f0a71c24289b44d6fee9ef79e10 rdf:first sg:person.01001125170.39
180 rdf:rest N9651df97b76649aaa6d722c709ce4a5e
181 N5748f7a8ef1147f794eb05c5c2c286b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Humans
183 rdf:type schema:DefinedTerm
184 N592403fb0e0844319c94afd4f457615c rdf:first sg:person.01224071104.01
185 rdf:rest rdf:nil
186 N7c64c6c6052848a888cf75f490ff798c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Antibodies, Monoclonal
188 rdf:type schema:DefinedTerm
189 N7eaca1b2223b4ef8ab7ae42e8e1879ac rdf:first sg:person.01151435377.39
190 rdf:rest N42599233534c47e2a2d78bf26fc43fa1
191 N819f6b74694f41a1b251e238d22b431b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Multimodal Imaging
193 rdf:type schema:DefinedTerm
194 N90345f1acc9e4f5bb6079aa368ecd48a rdf:first sg:person.01001654663.28
195 rdf:rest N7eaca1b2223b4ef8ab7ae42e8e1879ac
196 N9550fb9b2f5340f2acecca827c7653ab rdf:first sg:person.0653324404.03
197 rdf:rest N592403fb0e0844319c94afd4f457615c
198 N9651df97b76649aaa6d722c709ce4a5e rdf:first sg:person.01105624024.07
199 rdf:rest N0398ba0dca5d4968b0034c3a08ff0987
200 N9918f29ce04a4d1c9cb9832ae7ebd7fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Iodine Radioisotopes
202 rdf:type schema:DefinedTerm
203 Na008c97f5b704285a85cadf85defcd80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Male
205 rdf:type schema:DefinedTerm
206 Na1831bb965774a63a5dcdbcb665fda19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Immunoconjugates
208 rdf:type schema:DefinedTerm
209 Nb631c3aee99e4ce5b132d9317e8728b6 schema:name dimensions_id
210 schema:value pub.1003557788
211 rdf:type schema:PropertyValue
212 Nb751b69ab02741e49943fb97d16ca5f6 schema:name Springer Nature - SN SciGraph project
213 rdf:type schema:Organization
214 Nb8e7d816f2c3439caf9d31c9fc0a5159 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Middle Aged
216 rdf:type schema:DefinedTerm
217 Nbba8fa72b15c425a8a0c1ff73105e5f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
218 schema:name Treatment Outcome
219 rdf:type schema:DefinedTerm
220 Ncab0369f688a4c729dd0e71b57980dd1 schema:issueNumber 3
221 rdf:type schema:PublicationIssue
222 Nd22a09e179144cfeb5d0bc533f826a26 rdf:first sg:person.01157114464.91
223 rdf:rest N0d54fbbc54ed4169816511fbe25317ed
224 Ne67b5d8fbb8643c4b18991871a9988c4 schema:name doi
225 schema:value 10.1007/s13277-012-0362-y
226 rdf:type schema:PropertyValue
227 Neb4f5df1d3e94395a4fe7b5d40cc5560 rdf:first sg:person.01112242163.57
228 rdf:rest N27698898e3dd4300932dfa38f9de1e84
229 Neb5505af45ba4573b1af397376855d72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
230 schema:name Syndecan-1
231 rdf:type schema:DefinedTerm
232 Necd1775eca2146118a45055f1f2e04fe rdf:first sg:person.01240530667.47
233 rdf:rest Neb4f5df1d3e94395a4fe7b5d40cc5560
234 Nf89f3c6c970e48e1bfb769cc6a1f2f86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Radiometry
236 rdf:type schema:DefinedTerm
237 Nfb5557a1833341a4852e94da2a19a52b rdf:first sg:person.0774254522.22
238 rdf:rest N9550fb9b2f5340f2acecca827c7653ab
239 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
240 schema:name Medical and Health Sciences
241 rdf:type schema:DefinedTerm
242 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
243 schema:name Pharmacology and Pharmaceutical Sciences
244 rdf:type schema:DefinedTerm
245 sg:journal.1091981 schema:issn 1010-4283
246 1423-0380
247 schema:name Tumor Biology
248 schema:publisher Springer Nature
249 rdf:type schema:Periodical
250 sg:person.01001125170.39 schema:affiliation grid-institutes:grid.4817.a
251 schema:familyName Bardiès
252 schema:givenName Manuel
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001125170.39
254 rdf:type schema:Person
255 sg:person.01001654663.28 schema:affiliation grid-institutes:grid.4817.a
256 schema:familyName Barbet
257 schema:givenName Jacques
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001654663.28
259 rdf:type schema:Person
260 sg:person.01105624024.07 schema:affiliation grid-institutes:grid.4817.a
261 schema:familyName Davodeau
262 schema:givenName François
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105624024.07
264 rdf:type schema:Person
265 sg:person.01112242163.57 schema:affiliation grid-institutes:None
266 schema:familyName Ferrer
267 schema:givenName Ludovic
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112242163.57
269 rdf:type schema:Person
270 sg:person.01137036366.77 schema:affiliation grid-institutes:None
271 schema:familyName Supiot
272 schema:givenName Stéphane
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137036366.77
274 rdf:type schema:Person
275 sg:person.01145011737.42 schema:affiliation grid-institutes:None
276 schema:familyName Lacombe
277 schema:givenName Marie
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145011737.42
279 rdf:type schema:Person
280 sg:person.01151435377.39 schema:affiliation grid-institutes:grid.277151.7
281 schema:familyName Guillaume
282 schema:givenName Thierry
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151435377.39
284 rdf:type schema:Person
285 sg:person.01157114464.91 schema:affiliation grid-institutes:None
286 schema:familyName Wijdenes
287 schema:givenName John
288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157114464.91
289 rdf:type schema:Person
290 sg:person.01224071104.01 schema:affiliation grid-institutes:grid.4817.a
291 schema:familyName Cherel
292 schema:givenName Michel
293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224071104.01
294 rdf:type schema:Person
295 sg:person.01240530667.47 schema:affiliation grid-institutes:grid.4817.a
296 schema:familyName Rousseau
297 schema:givenName Caroline
298 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47
299 rdf:type schema:Person
300 sg:person.01334456404.06 schema:affiliation grid-institutes:grid.277151.7
301 schema:familyName Faivre-Chauvet
302 schema:givenName Alain
303 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334456404.06
304 rdf:type schema:Person
305 sg:person.016576267377.88 schema:affiliation grid-institutes:None
306 schema:familyName Baumgartner
307 schema:givenName Pierre
308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016576267377.88
309 rdf:type schema:Person
310 sg:person.0653324404.03 schema:affiliation grid-institutes:grid.277151.7
311 schema:familyName Kraeber-Bodéré
312 schema:givenName Françoise
313 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03
314 rdf:type schema:Person
315 sg:person.0732370777.35 schema:affiliation grid-institutes:grid.277151.7
316 schema:familyName Moreau
317 schema:givenName Philippe
318 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732370777.35
319 rdf:type schema:Person
320 sg:person.0774254522.22 schema:affiliation grid-institutes:grid.418189.d
321 schema:familyName Harousseau
322 schema:givenName Jean Luc
323 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774254522.22
324 rdf:type schema:Person
325 sg:pub.10.1007/s00259-005-1803-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025046486
326 https://doi.org/10.1007/s00259-005-1803-2
327 rdf:type schema:CreativeWork
328 sg:pub.10.1007/s002590050306 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015921857
329 https://doi.org/10.1007/s002590050306
330 rdf:type schema:CreativeWork
331 sg:pub.10.1007/s002620050289 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039961050
332 https://doi.org/10.1007/s002620050289
333 rdf:type schema:CreativeWork
334 sg:pub.10.1007/s10585-007-9125-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029972570
335 https://doi.org/10.1007/s10585-007-9125-3
336 rdf:type schema:CreativeWork
337 sg:pub.10.1038/bjc.1997.409 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019429566
338 https://doi.org/10.1038/bjc.1997.409
339 rdf:type schema:CreativeWork
340 sg:pub.10.1038/leu.2008.291 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002132702
341 https://doi.org/10.1038/leu.2008.291
342 rdf:type schema:CreativeWork
343 grid-institutes:None schema:alternateName Diaclone, Besancon, France
344 Medical Physics Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France
345 Nuclear Medicine Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France
346 Radiotherapy Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France
347 schema:name Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France
348 Diaclone, Besancon, France
349 Medical Physics Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France
350 Nuclear Medicine Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France
351 Radiotherapy Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France
352 rdf:type schema:Organization
353 grid-institutes:grid.277151.7 schema:alternateName Hematology Department, University Hospital, Nantes, France
354 Nuclear Medicine Department, University Hospital, Nantes, France
355 schema:name Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France
356 Hematology Department, University Hospital, Nantes, France
357 Nuclear Medicine Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France
358 Nuclear Medicine Department, University Hospital, Nantes, France
359 rdf:type schema:Organization
360 grid-institutes:grid.418189.d schema:alternateName Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France
361 schema:name Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France
362 Hematology Department, University Hospital, Nantes, France
363 rdf:type schema:Organization
364 grid-institutes:grid.4817.a schema:alternateName Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France
365 schema:name Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France
366 Nuclear Medicine Department, Comprehensive Cancer Center ICO Gauducheau, IRCNA, Saint Herblain, France
367 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...